ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

DCCP Board Approves Concept Of RFA, New, Competing Contracts

October 15, 1982

Approval Granted For New Formulation of Lupron Depot

July 29, 2011

Cancer Advocacy: Deal Returns $3M to Office of Women’s Health, Spends $3.5M On Workshops

August 1, 1997

ONS, ASCO, AACR Growth Surge Continues; Flex Political Muscles During DC Meetings

June 8, 1990

Advocacy Groups Form Council To Lobby For Cancer Programs To Benefit Minorities

April 28, 1995

Tobacco Company Liggett Gave $3.6 Million To Henschke For CT Screening Research.

March 28, 2008